Stockholm3 study is named the best scientific publication by the European Association of Urology
Stockholm3 – the future of prostate cancer diagnostics
New analysis in European Urology finds Stockholm3 cost effective for population-based screening
Want to take Stockholm3?
Prostate cancer is the second most common cancer in the world, 1.4 million men are diagnosed yearly. Early detection is the key to successful treatment. Currently, a number of healthcare providers offer Stockholm3.
Participants in clinical studies
More cases of aggressive cancers found
Fewer unnecessary biopsies
Reduced healthcare costs
A3P Biomedical’s lead product is Stockholm3, a blood test that combines protein markers, genetic markers and clinical data with a proprietary algorithm in order to detect aggressive prostate cancer at an early stage.
The European Commission recommends member states to implement organized screening of prostate cancer
September 26, 2022
A3P Biomedical forms Scientific Advisory Board
August 31, 2022
Stockholm3 in NICE Medtech Innovation Briefing for the UK
August 23, 2022